Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial
Conclusions In patients who underwent coronary stent implantation, the addition of cilostazol to aspirin therapy was associated with lower rates of cardiovascular and cerebrovascular events at 2 years compared with aspirin monotherapy.
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Angioplasty | Aspirin | Bleeding | Cardiology | Cardiovascular | Cilostazol | Clinical Trials | Coronary Angioplasty | Heart | Heart Attack | Ischemic Stroke | Percutaneous Coronary Intervention | Stroke